Identifying High-Risk Tumors within AJCC Stage IB–III Melanomas Using a Seven-Marker Immunohistochemical Signature

SIMPLE SUMMARY: Immunotherapy and targeted therapy are widely accepted for stage III and IV melanoma patients. Clinical investigation of adjuvant therapy in stage II melanoma has already started. Therefore, methods for relapse prediction in lower stage melanoma patients apart from sentinel node biop...

Descripción completa

Detalles Bibliográficos
Autores principales: Reschke, Robin, Gussek, Philipp, Ziemer, Mirjana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229951/
https://www.ncbi.nlm.nih.gov/pubmed/34200680
http://dx.doi.org/10.3390/cancers13122902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229951/
https://www.ncbi.nlm.nih.gov/pubmed/34200680
http://dx.doi.org/10.3390/cancers13122902

Ejemplares similares